






Metabolomics studies have pro-
vided new insights into molecular
disease mechanisms and individual
response to treatment. Large scale
metabolomics studies can greatly
contribute to building a solid
data and knowledge basis for fu-
ture disease prevention strategies as
well as better diagnostic and
therapeutic approaches (1). A
prerequisite, however, is that data
from a sufficient number of bio-
samples are available. This goal
can only be achieved by gathering
many samples from different
cohorts and requiring that the
quality of these samples is appro-
priate to generate reliable and
reproducible results.
The impact of the preanalytical
procedures on the stability of the
human metabolome has been
previously described. In particular,
systematic simulation of different
preanalytical procedures performed
on urine and blood serum and
plasma have highlighted how the
concentration of some key metabo-
lites is altered via 2 main mecha-
nisms: enzymatic activity, mainly,
but not exclusively, attributable to
the presence of cells; and redox
reactions occurring among metabo-
lites and between metabolites and
dioxygen (2, 3). The results have
led to the development of
international specifications such as
the 2016 European Committee for
Standardization (CEN)/TS 16 945
Specifications for molecular
in vitro diagnostic examinations—
Specifications for preexamination
processes for metabolomics in
urine, venous blood serum, and
plasma.
We performed a comprehen-
sive nuclear magnetic resonance
(NMR)-based metabolomics study
of human blood serum and plasma
(EDTA-plasma) from, respectively,
5 and 8 leading European popula-
tion cohorts from the BBMRI-LPC
consortium. We addressed the
extent to which samples of different
cohorts were suitable to be used
together for metabolomics studies
and whether data integration of
studies performed on such samples
was feasible and reliable. The analy-
sis was performed via 1H NMR, a
highly reproducible tool for untar-
geted fingerprinting and profiling
(4), where all metabolites above the
1 mM detection limit were mea-
sured simultaneously. Each partici-
pating biobank provided serum and
plasma samples from 30 healthy
volunteers with equal share of males
and females.
Multivariate statistics revealed
a clear discrimination of the
samples based on the biobank of or-
igin. The accuracy for classification
(96% for plasma and 98% for se-
rum, Fig. 1) was assessed by means
of a Monte Carlo cross-validation
scheme; each dataset was randomly
divided into a training set (90% of
the data) and a test set (10% of the
data). The training set was used to
build the model, whereas the test
set was used to validate its discrimi-
nant and predictive power; this
operation was repeated 500 times.
The differences were mainly attrib-
utable to a small but relevant set of
metabolites that showed different
mean concentration values in sam-
ples from different biobanks. From
an ex post analysis of the standard
operating procedures adopted by
each biobank, we could interpret
the observed trends in terms of dif-
ferences in preanalytical procedures.
A major effect was attributable to
the delayed separation of plasma
and serum from the blood cellular
components; erythrocytes, when re-
moved from the circulation, exhibit
severe disturbance of the glycolytic
flow (5), which manifests itself
mainly in glucose consumption
and lactate accumulation. In fact,
unusual concentrations of these 2
metabolites, which are key bio-
markers of a series of metabolic
dysfunctions, were observed for the
biobanks allowing for 72 h delayed
sample preparation (i.e., centrifuga-
tion). Another critical step con-
cerned the delay between serum/
plasma separation and sample freez-
ing. This phase is not adequately
regulated by the standard operating
procedures of the various biobanks,
which translates, for example, into
variable concentrations of citrate
within samples from the same bio-
banks as well as from the different
biobanks.
The situation of Fig. 1 is often
encountered in metabolomics stud-
ies based on multicenter cohorts
whenever samples are not collected
under strictly controlled conditions,
and can be aggravated by the use of
different additives (such as gel
separators) that might interfere
with components of the sample
metabolome. The inaccurate quan-
tification of small molecule bio-
markers might severely affect the
outcome of metabolomics studies,
introducing artificial noise, and
thus weakening the profiling perfor-
mance of the analytical method. In
summary, 2 main conclusions can
be derived from the present contri-
bution. First, samples from existing
cohorts should be used with care
and possibly after reviewing the
operating procedures adopted for
sample collection, processing, and
storage. Second, the biobanks inter-
ested in creating novel collections
to be used for metabolomics must
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adopt procedures that comply with
the existing CEN/ISO standards.
Nonstandard Abbreviations: CEN,
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Fig. 1. Supervised discrimination obtained via orthogonal projections to latent structures-discriminant analysis used to increase
the separation of the analyzed groups. In the score plots, each dot represents a different sample; samples from different bio-
banks are represented with different colors.
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A Large Number of Fresh
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assays will help mitigate both pa-
tient and clinician confusion re-
garding disparate results obtained
from various manufacturers.
Despite standards being established
in 1999, the 2008 recommendation
from the National Academy of
Clinical Biochemistry laboratory
practice guidelines to include the
manufacturer of the tPSA on the re-
port is still prudent (1). The recent
paper by Ferraro and colleagues fur-
ther emphasizes the need that
patients be monitored by the same
method (or measuring system, MS)
but also states “that the remaining
clinically relevant systematic biases
among MSs could be successfully
removed by a mathematical recali-
bration process by using a suitable
reference material” (2). This is an
intriguing statement that depends
at least in part in a mathematical re-
lationship that is consistent over a
large number of samples, over a
wider and higher analytical range,
and with different MSs.
In their publication, Ferraro
and colleagues use a sufficient num-
ber of samples (n¼ 135 serum sam-
ples for tPSA) for the method
comparisons as suggested by Linnet
(3). However, the results reported
in the publication only ranged from
approximately 1 mg/L to 50 mg/L
and tPSA was measured by only 4
MSs (Abbott Alinity, Beckman
Access, Roche Cobas, and Siemens
Atellica) (2). This range does not
capture those patients with very low
concentrations (i.e., Abbott tPSA
<0.97 mg/L) or with very high con-
centrations (Abbott tPSA
>48.8 mg/L) who are routinely ob-
served in clinical practice (4).
Moreover, the 4 MSs do not cap-
ture all relevant MSs. According to
the combined Institute for Quality
Management in Healthcare
(Canada) and the Royal College of
Pathologists of Australasia Quality
Assurance Programs, approximately
12% of more than 200 sites use the
Ortho Clinical Diagnostics MS for
tPSA measurement (see October 2,
2020 issued report). As our hospital
site recently transitioned from the
Abbott ARCHITECT tPSA assay
to the Ortho VITROS XT 7600
tPSA assay, our objective was to as-
sess the percentage difference be-
tween Ortho tPSA from Abbott
tPSA across various analytical
ranges in fresh serum samples tested
by both methods over 15 weeks
(dual reporting to enable rebaselin-
ing tPSA) (4, 5).
During the period of dual
reporting (May 2020 to August
2020 to allow clinicians to rebase-
line patients), there were 1101 sam-
ples reported by both tPSA
methods, with 18% yielding at least
1 result below the limit of quantifi-
cation (LoQ) for either assay. For
the 538 samples falling within the
0.97 mg/L to 48.8 mg/L range used
in the Ferraro study, the median
(25th to 75th percentiles) percent-
age difference [(Ortho
tPSAAbbott tPSA)/Abbott
tPSA 100%] was 14.6% (8.6 to
21.0). A similar difference of
13.3% (8.0 to 20.0) was observed
in the LoQ to 0.96 mg/L samples
(n¼ 265) (P¼ 0.35, Kruskal–
Wallis all pairwise comparisons
with Conover-Iman, StatsDirect
Statistical Software v.3.2.7).
However, for the 103 samples
above 48.8 mg/L, the percentage
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